Co-Diagnostics hosted an investor and analyst presentation on September 16, 2026, covering its ReadyGo Diagnostics collaboration, Co-Dx PCR platform, development activities, Manufacturing initiatives and India operations. The presentation materials give investors the company’s stated agenda for its collaboration, platform development and operating initiatives.

Key Highlights

  • Dwight Egan signed the document as Co-Diagnostics’ Chief Executive Officer and Principal Executive Officer.
  • The presentation materials.
  • The presentation will address manufacturing initiatives and operations in India.

Presentation to

Cover Platform and Operations The presentation will address manufacturing initiatives and operations in India. It will also cover matters related to the company’s collaboration with ReadyGo Diagnostics Ltd. and activities connected with the Co-Dx PCR platform. The materials for the presentation. The presentation will be held for investors and analysts.

Corporate Sign-Off Dwight Egan signed on behalf of Co-Diagnostics (NASDAQ

CODX (NASDAQ: CODX)) as Chief Executive Officer and Principal Executive Officer. The document was dated September 16, 2026.